raising questions about FDA's drug approval and surveillance process
A firestorm of press is raising questions about FDA's drug approval and surveillance process. ...
Table of Contents
- raising questions about FDA's drug approval and surveillance process
- Reps will be touting evidence that suggests carvedilol is better than metoprolol for diabetes patients
- what really works for fibromyalgia
- Reps will be saying that amlodipine (Norvasc) reduces the risk of cardiovascular events
- BiDil will be the first drug approved specifically for African Americans
- Light therapy is often as effective as antidepressants for seasonal affective disorder (SAD)
- Ritalin, Adderall, and other stimulants to enhance test scores
- flecainide (Tambocor) or propafenone (Rythmol) written "take as needed for atrial fibrillation"
- Tysabri (tie-SAB-ree), the latest treatment for multiple sclerosis (MS)
- Aricept and other cholinesterase inhibitors for patients with multiple sclerosis
- the risk of bone loss in women using Depo-Provera
- whether testosterone is appropriate for treating sexual dysfunction in women
- More women with EARLY breast cancer will be treated with an aromatase inhibitor
- Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC)
- DHEA for weight loss
- End of year is a good time to reflect on trustworthy drug information that is relevant to practice.